(NASDAQ: ARCT) Arcturus Therapeutics Holdings's forecast annual revenue growth rate of 22.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.52%.
Arcturus Therapeutics Holdings's revenue in 2026 is $29,367,000.On average, 15 Wall Street analysts forecast ARCT's revenue for 2026 to be $517,868,317, with the lowest ARCT revenue forecast at $232,074,358, and the highest ARCT revenue forecast at $984,859,341. On average, 15 Wall Street analysts forecast ARCT's revenue for 2027 to be $1,075,528,931, with the lowest ARCT revenue forecast at $167,127,646, and the highest ARCT revenue forecast at $3,814,091,629.
In 2028, ARCT is forecast to generate $1,530,894,919 in revenue, with the lowest revenue forecast at $197,767,714 and the highest revenue forecast at $3,188,784,111.